Howarth joins team at world-class pharmaceutical manufacturing centre

Published: 21-Jan-2014

Air technology solutions to be deployed at South Devon Healthcare NHS Foundation Trust\'s new facility


Howorth Air Technology has secured a vital role in the project to build South Devon Healthcare NHS Foundation Trust’s new multi-million pound Pharmaceutical Manufacturing Centre (PMU).

Howorth’s pharmaceutical division is working within the integrated team for Cowlin Construction, part of the Balfour Beatty group, erecting the new pharmaceutical centre, which will feature world-class design and equipment.

The PMU is scheduled for completion late 2014.

The two-storey building, which is 78,000sq ft in size, will incorporate high-quality materials, and is designed to be highly sustainable, aiming for a BREEAM rating of ‘Very Good’.

quotation This is an exciting and ambitious development to create a centre of excellence committed to supplying and investing in the development of essential pharmaceuticals throughout the UK and internationally, with any operating surplus being re-invested back into our local NHS and patient care

Howorth is fully responsible for the provision of more than 2,000sq m of specialised manufacturing facilities within the PMU, including graded cleanrooms, sterile areas, dispensary, specialist HVAC, process equipment design, installation and validation. This multi-million pound internal specialist fit-out project included specialist water treatment, licensed production and the management of a substantial additional budget for new equipment.

This consolidation and expansion project includes new process equipment, the relocation of existing equipment, and the consolidation of three operational locations including the Quality Control Group. Howorth has been working on the front end of the project for more than two years and has been an integral member of the design team together with Lacey Hickie Caley (LHC Architects), Hoare Lea and NG Bailey.

Dr Nicholas Frampton, managing director of the PMU, said: "This is an exciting and ambitious development to create a centre of excellence committed to supplying and investing in the development of essential pharmaceuticals throughout the UK and internationally, with any operating surplus being re-invested back into our local NHS and patient care.”

You may also like